Avalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on Monday

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) is expected to release its Q4 2024 earnings data before the market opens on Monday, May 12th. Analysts expect Avalo Therapeutics to post earnings of ($1.07) per share for the quarter.

Avalo Therapeutics Stock Performance

Shares of AVTX opened at $5.04 on Monday. Avalo Therapeutics has a fifty-two week low of $4.15 and a fifty-two week high of $16.00. The firm has a 50-day simple moving average of $6.37 and a 200-day simple moving average of $8.35.

Wall Street Analyst Weigh In

AVTX has been the subject of a number of recent research reports. Piper Sandler started coverage on Avalo Therapeutics in a research report on Friday, February 28th. They set an "overweight" rating and a $48.00 price objective for the company. HC Wainwright reaffirmed a "neutral" rating on shares of Avalo Therapeutics in a report on Thursday, March 20th. Jefferies Financial Group started coverage on shares of Avalo Therapeutics in a research note on Tuesday, March 25th. They issued a "buy" rating and a $23.00 price objective on the stock. Wedbush restated an "outperform" rating and set a $18.00 price objective on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Finally, Stifel Nicolaus began coverage on shares of Avalo Therapeutics in a report on Tuesday, March 25th. They issued a "buy" rating and a $36.00 target price on the stock. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Avalo Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $33.00.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.